VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Q3 sales

<< Previous

Bullboard Posts

Next >>

Post by theNormon Oct 04, 2022 11:04pm

139 Views

Post# 35005824

Q3 sales

ending Sept 30 don't have to be reported on Sedar for 2 months nov 30 deadline probably. That will cover july 1 to Sept 30 Google "friends and family effect" or maybe try Investopedia.com where you can also research non-disclosure agreement or NDA

<< Previous

Bullboard Posts

Next >>

FE Battery Metals begins 2024 winter drill program